Theranostics is a groundbreaking topic that's reshaping how we diagnose and treat cancer. It's a cutting-edge approach in cancer care, combining diagnosing and treating cancer using the same molecular tools. Theranostics has the spotlight because it's delivering on a promise we've been chasing for years in cancer care, truly personalized targeted treatment with fewer side effects than traditional options.   Guests: Lindsay Williams, MBA, CNMT, R.T.(N)(CT)(ARRT) Pharmacy Sourcing Portfolio Executive Vizient   Setu Shah, MPH Sr. Associate, Intelligence Sg2   Janna Laton, MBA, CNMT, NMTCB(CT), R.T.(R)(N)(MR)(ARRT) Independent Contributor and SME   Host: Adam Fairbourn, MBA, CNMT Senior Director, Contract Services Vizient, Capital Equipment Solutions   Show Notes: [00:45] Defining Theranostics and why it’s getting attention [02:10] “See what you treat and treat what you see” captures the power of Theranostics [03:10] Why neuroendocrine tumors and prostate cancer are particularly well suited for this approach [03:50] Prostate specific membrane antigen or PSMA targeted imaging and treatment work and results [05:28] How Theranostics compares with more traditional cancer treatments in terms of precision and side effects   Links | Resources: Vizient article - https://www.vizientinc.com/insights/diagnostic-imaging Sg2 Perspectives Podcast: Transforming Cancer Care Delivery Sg2 Perspectives Podcast: Cell and Gene Therapy in Practice   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed